In this editorial, we address the relative benefits of lowering elevated plasma lipoprotein(a) (Lp(a)), a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), with a proprotein convertase subtilisin/ kexin type 9 (PCSK9) monoclonal antibody and lipoprotein apheresis (LA) in the light of emerging biologics specifically targeted at the apolipoprotein(a) gene.
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Among the therapeutic interventions aimed at reducing Lp(a), the role of PCSK9 inhibitors within the treatment of high risk hypercholesterolemic patients with ASCVD has recently been emphasized. 1 Besides dramatic low-density lipoprotein (LDL)-cholesterol reduction (about 60%), PCSK9 antagonists have a clear effect in lowering plasma Lp(a) concentrations. Data from both randomised controlled trials 2,3 and real-world cohorts have reported mean Lp(a) reductions of about 20-25%. 4, 5 However, Lp(a) lowering with PCSK9 monoclonal antibodies appears to be mediated not only by LDL receptor upregulation, 6 but possibly also by the inhibition of the production of Lp(a) particles. As monotherapy, the major impact of PCSK9 monoclonal antibodies may be on Lp(a) production, but in combination with statins, when the LDL receptor is maximally upregulated, the principal mechanism involves an accelerated catabolism of Lp(a) holoparticles. 7 Other therapies affecting Lp(a) levels also act on biosynthesis, e.g. in particular extended release niacin, decreasing the production of both Lp(a) and Lp(a)-apo-B-100. 8 While PCSK9 antagonism on average lowers plasma Lp(a) levels, the therapeutic response is variable and may depend on baseline levels. In a secondary analysis of the FOURIER study, a 16% Lp(a) lowering was found in patients with baseline levels greater than 66 mg/dL. 9 A post-hoc analysis of the ODYSSEY OUTCOMES study showed that while median absolute changes in LDL-cholesterol with alirocumab were consistent across all quartiles (range -53.3%/-54.1%), absolute changes in Lp(a) increased progressively with increasing quartile -5.12% (quartile 2), -9.8% (quartile 3) and -20.2% (quartile 4). Lp(a) reduction with alirocumab was associated with a lower incidence of major adverse cardiovascular events and non-fatal myocardial infarctions after adjustment for baseline and absolute changes of LDL-cholesterol. There was no relationship between the reduction of Lp(a) and stroke or mortality. 10 Different conclusions were reached in a very recent evaluation of statin data on cardiovascular risk in patients with elevated, i.e. 50 mg/dL or greater, versus lower Lp(a) levels: cardiovascular risk was 47% higher in statin-treated patients (adjusted hazard ratio (HR) 1.47, 95% confidence interval (CI) 1.25-1.73) versus 26% (adjusted HR 1.26, 95% CI 1.06-1.50) for those on placebo. 11 This shows a mechanistic difference between the two drug classes, i.e. a specific effect on Lp(a) by PCSK9 antagonists, versus a raised Lp(a) associated risk in patients on statin treatment, particularly in those with Lp(a) greater than 50 mg/dL. This study supports the conclusion that risks associated with LDL-cholesterol and Lp(a) are independent and that when the LDL-cholesterol attributable risk is reduced by statins, the Lp(a) associated risk becomes pivotal. 12 For patients with progressive ASCVD and high plasma Lp(a), a potentially valuable therapeutic option is LA, which can be carried out by different methodologies and at different time intervals. However, it is noteworthy that there are significant differences in the impact of different types of LA on inflammatory markers. While the reduction in high sensitivity C-reactive protein is universal with all types of LA, procedures based on whole blood absorption, plasma absorption and plasma filtration tend to raise plasma interleukin (IL)-6 levels. 13 In the study by Zenti et al., LA with the HELP procedure was associated with a 21% increase in IL-6.
14 Conversely, LA involving the direct absorption of lipids by the DALI procedure lowered IL-6 levels. 15 The ASCVD benefit of Lp(a) reduction with PCSK9 inhibition may be additive to that on LDL-cholesterol. Moriarty et al., in the ODYSSEY ESCAPE study, 16 however, failed to note in heterozygous familial hypercholesterolaemia with established ASCVD any additive effect of alirocumab on top of LA on Lp(a) levels. The possibility of an additional cardiovascular disease benefit by the combined treatments has recently been challenged by Stiekema et al. 17 demonstrating that, in patients with Lp(a) basal levels of 80 mg/dL, 3 months evolocumab treatment did not reduce arterial wall inflammation in the presence of modest Lp(a) attenuation (-14%). It is thus likely that the arterial benefit of LDL-cholesterol reduction with a PCSK9 antagonist may be blunted in patients with persistently elevated Lp(a).
A more reliable indication may come from studies with selective apheretic procedures just for Lp(a). 18 A total of 30 coronary patients with Lp(a) greater than 50 mg/dL, and LDL-cholesterol of 97 mg/dL or less on chronic statin were prospectively evaluated after weekly treatments with Lp(a) Lipopak columns versus atorvastatin only; quantitative coronary angiography was performed at baseline and after an 18-month treatment. Compared with statin treatment alone, combination treatment was associated with a 75% larger Lp(a) lowering and significant reductions in coronary atheroma burden and carotid intima-media thickness. 19 For patients with isolated marked elevation in Lp(a) and progressive ASCVD, LA would be a more appropriate therapy than the use of PCSK9 monoclonal antibodies. In a real-world study, Zenti et al. showed that in patients with hyperLp(a)lipoproteinemia, LA was more effective than PCSK9 inhibitors in reducing Lp(a), i.e. 69% versus 12%.
14 Recent guidelines 20 provide good evidence for the efficacy of LA and criteria for selecting patients. Stefanutti et al. also emphasised that LA columns may absorb PCSK9 antagonists and administration of these agents should be done immediately after the procedure. 20 In an extension of the theories articulated by Velji et al. 21 and Sampietro et al., 22 we propose that combined treatment with PCSK9 monoclonal antibodies and apheresis may be preferable in certain hypercholesterolaemic patients with high Lp(a), because of the combined benefits of both approaches in lowering LDLcholesterol, triglyceride-rich lipoproteins, inflammation, haemorrheology and Lp(a). The value of adding nicotinic acid to apheresis or to PCSK9 monoclonal antibodies for lowering Lp(a) merits investigation. Disputations concerning the relative advantages of PCSK9 inhibitors versus LA in treating high Lp(a) may appear irrelevant with the advent of RNA-based therapies, which block the production of Lp(a) particles. 23 
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